The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Laboratoire Franais Du Fractionnement Et Des Biotechnologies competitive analysis

Loading summary...

Latest patents of Laboratoire Franais Du Fractionnement Et Des Biotechnologies opposed by its competitors

Explore Laboratoire Franais Du Fractionnement Et Des Biotechnologies's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP3481415
Sep 6, 2023Stable Liquid Fibrinogen3
EP3806891
Aug 2, 2023Combination Of Factor Vii And An Anti-Factor Ix/X Bispecific Antibody1
EP2651978
Jan 12, 2022Use Of An Antibody Directed Against A Membrane Protein1
EP3390452
May 26, 2021New Use Of An Anti-Cd303 Transmembrane Protein Antibody1
EP3277723
Jun 17, 2020Cell Line Overexpressing Human Cd303 Antigen1
EP3116527
Sep 4, 2019Method For Preparing Human Plasma Proteins1
EP2345425
Jul 11, 2018Immunoglobulin G (Igg) Concentrate Depleted Of Anti-A And Anti-B Antibodies And Of Polyreactive Iggs2

Latest PTAB cases involving Laboratoire Franais Du Fractionnement Et Des Biotechnologies

Discover the latest PTAB cases involving Laboratoire Franais Du Fractionnement Et Des Biotechnologies, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Laboratoire Franais Du Fractionnement Et Des Biotechnologies with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
LABORATOIRE FRANAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES - 10 - -
MARCHANT2 - - -
STRAWMAN339 - - -
TAKEDA PHARMACEUTICALS3 - - -